TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET
Company Participants
Jenna Bosco – Investor Relations
Michael Weiss – Chairman and Chief Executive Officer
Adam Waldman – Chief Commercialization Officer
Sean Power – Chief Financial Officer
Conference Call Participants
Josh Schimmer – Evercore ISI
Ed White – H. C. Wainwright
Prakhar Agrawal – Cantor Fitzgerald
Sahil Kazmi – B. Riley Securities
Operator
Greetings, and welcome to the TG Therapeutics Fourth Quarter and Year-End 2022 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Jenna Bosco. Thank you and you may begin.
Jenna Bosco
Thank you. Welcome, everyone, and thanks for joining us this morning. I’m Jenna Bosco, and with me today to discuss the fourth quarter and year-end 2022 financial results and provide a business update are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercialization Officer; and Sean Power, our Chief Financial Officer.
Following our Safe Harbor statement, Mike will provide an overview of our recent corporate developments, Adam will provide an update on our commercialization efforts, and Sean will provide a brief overview of our financial results before turning the call over to the operator to begin the Q&A session.
Before we begin, I’d like to remind everyone that we will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about our anticipated future operating and financial performance, projected regulatory milestones, clinical development plans and expectations for our marketed products.
TG cautions that these forward-looking statements are subject to risks that may cause our actual
- Read more current TGTX analysis and news
- View all earnings call transcripts